A double-blind phase III randomised controlled trial investigated the use of abiraterone acetate in men with metastatic castration-resistant prostate cancer with no previous chemotherapy.
A double-blind phase III randomised controlled trial reported results on December 10,2012. The authors investigated the use of abiraterone acetate in men with metastatic castration-resistant prostate cancer with no previous chemotherapy.